Vimarsana
Biggest News Aggregation in the World

Grave Orbitopathy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Grave Orbitopathy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Grave Orbitopathy Today - Breaking & Trending Today

Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease - Vimarsana News

Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY - Vimarsana News

AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency...

Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA - Vimarsana News

Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA

ROCKVILLIE, MD. and SUZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company

TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED) - Vimarsana News

TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED)

-- First and only medicine approved in Brazil for the treatment of active TED, a serious, progressive, debilitating and potentially vision-threatening rare autoimmune disease --

TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED) - Horizon Therapeutics (NASDAQ:HZNP) - Vimarsana News

TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED) - Horizon Therapeutics (NASDAQ:HZNP)

-- First and only medicine approved in Brazil for the treatment of active TED, a serious, progressive, debilitating and potentially vision-threatening rare autoimmune disease -- Horizon Therapeutics plc (NASDAQ:HZNP)